Ultrasonic therapeutic device for neurodegenerative diseases and method of use thereof

Abstract

The present invention relates to the field of medical device technology, and in particular to an ultrasonic therapeutic device for neurodegenerative diseases and a method of using the same. An ultrasonic therapeutic device for neurodegenerative diseases comprises: a host and a helmet assembly; a probe fixing assembly is provided on the helmet assembly, an ultrasonic circulator is provided on the probe fixing assembly, and the host is electrically connected to the ultrasonic transducer. The device uses low-intensity weakly focused ultrasound to continuously stimulate intracranial functional nuclei, uses transcranial ultrasound imaging to determine the location of ultrasound stimulation, determines the intensity of treatment through ultrasound signal feedback monitoring, and monitors near-infrared cerebral blood flow signals to grasp the real-time treatment effect. The device of the present invention can be used for the treatment of Parkinson's disease, Alzheimer's disease, hepatolenticular degeneration, and amnesia, and can be used to improve insomnia symptoms. It can also be used to treat drug, tobacco, and alcohol addiction. The device provided by the present invention achieves the treatment of specific diseases by continuously stimulating different intracranial functional nuclei using low-intensity weakly focused ultrasound.

Description

Technical Field

[0001] The present invention relates to the technical field of medical devices, and in particular to an ultrasonic therapeutic device for treating neurodegenerative diseases and a method for using the same. Background Art

[0002] As the trend of population aging accelerates in the world, it is particularly prominent in my country. The incidence of neurodegenerative diseases and the social medical burden are increasing rapidly, which is a social problem that needs to be paid close attention to. At present, there is a lack of effective clinical treatment for neurodegenerative diseases such as Parkinson's disease, ALS, and Alzheimer's disease. Studies have found that acoustic, optical, electrical, and magnetic neurophysical stimulation methods are expected to provide a new method for the treatment of neurodegenerative diseases, and have become a research hotspot at home and abroad. Various neuromodulation technologies have various advantages and disadvantages. Among them, low-intensity ultrasound has attracted more and more researchers' attention due to its good bone penetration and focusing performance. However, among the domestic research teams conducting low-intensity brain ultrasound regulation, our team has received support from the 2021 Shanghai Key Clinical Research Project, and was the first in China to pass the hospital ethics review and initiate clinical research. In the process of clinical research, we found that traditional ultrasound treatment equipment is large in size, and the frequency and focusing range are not set according to the characteristics of brain ultrasound. The treatment intensity and direction cannot be adjusted in real time according to the condition and location of the disease. There is a lack of feedback monitoring, and the treatment effect is unknown. It is difficult to effectively ensure the safety of patient treatment and adapt to the needs of brain ultrasound treatment. Moreover, the treatment process is cumbersome. For patients with this type of neurodegeneration, they need to be accompanied by a caregiver when they go to the hospital, and medical resources are tight, so patients have to go to the hospital for treatment multiple times a day, and patient compliance is extremely poor. The treatment of patients with neurodegeneration requires long-term home treatment, and current ultrasound equipment is difficult to meet this need. There is an urgent need to develop a wearable brain ultrasound treatment device for neurodegenerative diseases with a feedback monitoring device. Summary of the invention

[0003] The technical solution adopted by the present invention utilizes low-intensity weakly focused ultrasound to continuously stimulate intracranial functional nuclei, utilizes transcranial ultrasound imaging to determine the location of ultrasound stimulation, determines the intensity of treatment through ultrasound signal feedback monitoring, and grasps the real-time treatment effect through near-infrared cerebral blood flow signal monitoring. The ultrasonic therapeutic device for neurodegenerative diseases provided by the present invention can be used to treat Parkinson's disease, Alzheimer's disease, hepatolenticular degeneration, and amnesia, and can be used to improve insomnia symptoms. In addition, according to research, this ultrasonic therapeutic device for neurodegenerative diseases can also be used to treat drug, tobacco and alcohol addiction behaviors. The device provided by the present invention achieves the treatment of specific diseases by continuously stimulating different intracranial functional nuclei using low-intensity weakly focused ultrasound.

[0004] In a first aspect, the present invention provides an ultrasonic therapeutic apparatus for neurodegenerative diseases, comprising: a host 10 and a helmet assembly; the helmet assembly is provided with a probe fixing assembly 20, the probe fixing assembly comprising an annular rod 201, a connecting portion 202, an adjustment buckle 1 203, an adjustment buckle 204, a hemispherical frame 205, a connecting piece 206, and a movable adjustment assembly 207; the hemispherical frame 205 is composed of a plurality of mutually connected slide rails and vertical rods, the bottom of the vertical rods being connected to the annular rod 201 The adjusting buckle 204 is arranged on the annular rod 201, the annular rod 201 is provided with connecting pieces 206 on both sides, the connecting piece 206 is connected with the connecting part 202, the adjusting buckle 1 203 is arranged on the connecting part 202, the near infrared light source probe 9 and the near infrared light receiving probe 11 are arranged on the hemispherical frame 205, and the moving adjusting component 207 includes a slide rail 1 208, a slide rail 209, a guide sleeve 1 2071, a connecting rod 2072, and a guide sleeve 2073. The movable adjustment component 207 is arranged between the upper and lower adjacent slide rails through the guide sleeve 1 2071, and the two guide sleeves 2071 are connected by a connecting rod 2072. The guide sleeve 2073 is arranged on the connecting rod 2072, and the ultrasonic transmitting probe 7 and the ultrasonic receiving probe 8 are respectively arranged on both sides of the guide sleeve 2073; the movable adjustment component 207 has two groups, which are respectively arranged on both sides of the rear part of the hemispherical frame 205 structure to perform ultrasonic treatment on both sides of the back of the brain; an ultrasonic transducer is also arranged on the probe fixing component, and the host is electrically connected to the ultrasonic transducer. The ultrasonic stimulation position is determined by intracranial ultrasonic imaging of the ultrasonic transmitting probe 7 and the ultrasonic receiving probe 8. The ultrasonic stimulation position is the clearest position of intracranial ultrasonic imaging. The ultrasonic treatment intensity is adjusted in real time by the host according to the condition of the disease and the ultrasonic stimulation position, and the treatment position is adjusted in real time by the movable adjustment component 207. The near-infrared light source probe 9 and the near-infrared light receiving probe 11 realize near-infrared brain function imaging monitoring, and the treatment effect can be monitored in real time.

[0005] Furthermore, the host is provided with a power supply module, a touch screen, an ultrasonic host, a main control module, a near-infrared light emitting module, and a near-infrared light receiving module; the touch screen, the ultrasonic host, the near-infrared light emitting module, and the near-infrared light receiving module are electrically connected to the main control module respectively; the power supply module is electrically connected to the touch screen, the ultrasonic host, the near-infrared light emitting module, the near-infrared light receiving module, and the main control module; there are multiple near-infrared light source probes, which are electrically connected to the near-infrared light emitting modules respectively; there are multiple near-infrared light receiving probes, which are electrically connected to the near-infrared light receiving modules respectively; the ultrasonic transmitting probe and the ultrasonic receiving probe are electrically connected to the ultrasonic host.

[0006] In a second aspect, the present invention provides a method for transmitting ultrasound to the head using an ultrasound therapeutic apparatus for neurodegenerative diseases, the method comprising the following steps:

[0007] S1: Put the helmet assembly on the patient's head and start the ultrasound host; perform intracranial ultrasound imaging through the ultrasound transmitting probe and the ultrasound receiving probe to determine the ultrasound stimulation position, which is the clearest position of intracranial ultrasound imaging; start the near-infrared light transmitting module and the near-infrared light receiving module to perform near-infrared brain function imaging monitoring on the patient through the near-infrared light source probe and the near-infrared light receiving probe to determine the ultrasound stimulation position, which is the area of ​​insufficient cerebral microblood flow shown by the near-infrared brain function imaging;

[0008] S2: Adjust the movable adjustment component so that the ultrasonic transmitting probe and the ultrasonic receiving probe are aligned with the ultrasonic stimulation position in S1;

[0009] S3: The ultrasonic transmitting probe generates ultrasonic waves toward the ultrasonic stimulation position, and the ultrasonic receiving probe receives and feedbacks the sound wave intensity; the near-infrared light receiving probe monitors the near-infrared cerebral blood flow signal in real time, and monitors the treatment effect in real time.

[0010] Furthermore, the ultrasound is low-intensity weakly focused ultrasound.

[0011] Furthermore, the ultrasound emitted in step S3 has a focusing diameter range of 1 mm to 20 mm and an ultrasound intensity of 0.5 w / cm 2 ~3w / cm 2 .

[0012] In a third aspect, the present invention provides a method for transmitting ultrasound to the head by an ultrasound therapeutic device for neurodegenerative diseases, wherein the ultrasound stimulation position is, for Parkinson's disease, the substantia nigra and striatum area; for ALS, the motor cortex area; for Wilson's disease, the lenticular nucleus area; and for Alzheimer's disease, the area of ​​insufficient cerebral microblood flow shown by near-infrared brain functional imaging is widely irradiated.

[0013] In a fourth aspect, the present invention provides a method for transmitting ultrasound to the head using an ultrasound therapeutic device for neurodegenerative diseases. When treating insomnia, the ultrasound stimulation location is the pineal gland area; when treating drug, tobacco and alcohol addiction behaviors, the ultrasound stimulation location is the nucleus accumbens area; when treating amnesia, the ultrasound stimulation location is the hippocampus area.

[0014] In a fifth aspect, the present invention provides an ultrasonic therapeutic apparatus for neurodegenerative diseases, the application scope of which includes the treatment and improvement of Parkinson's disease, amyotrophic lateral sclerosis, hepatolenticular degeneration, Alzheimer's disease, insomnia, drug, tobacco and alcohol addiction behaviors and / or amnesia.

[0015] The present invention provides some other applications of the above-mentioned ultrasonic therapeutic apparatus for neurodegenerative diseases, including its use in the treatment of insomnia, the treatment of hepatolenticular degeneration, and the treatment of tobacco and alcohol addiction.

[0016] Beneficial Effects

[0017] Compared with the related art, the present invention has the following beneficial effects:

[0018] The present invention provides a wearable brain ultrasound treatment device for neurodegenerative diseases with a feedback monitoring device. The ultrasound treatment device determines the ultrasound stimulation position through intracranial ultrasound imaging, adjusts the ultrasound treatment intensity in real time through the host according to the condition of the disease and the ultrasound stimulation position, adjusts the treatment position in real time through the mobile adjustment component, improves the accuracy of the treatment lesion position, realizes near-infrared brain function imaging monitoring through an infrared probe, and can monitor the treatment effect in real time, so that the patient's cure rate is high and the treatment effect is good.

[0019] The ultrasonic treatment device consists of a main unit and a helmet assembly. It has good portability, high integration, small size, low cost, and can meet the requirements for home use. The patient only needs to wear the helmet assembly on the head and control the main unit to complete the treatment. It is easy to use. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 The present invention is a schematic diagram of the structural connection of an ultrasonic therapeutic apparatus for neurodegenerative diseases.

[0021] Figure 2 The present invention is a schematic structural diagram of the front side of a probe fixing assembly of an ultrasonic therapeutic apparatus for treating neurodegenerative diseases.

[0022] Figure 3 The present invention is a schematic structural diagram of the rear side of a probe fixing assembly in an ultrasonic therapeutic apparatus for neurodegenerative diseases.

[0023] Figure 4 This is a partial enlarged view of the position of a movable adjustment component on a probe fixing component in an ultrasonic therapeutic apparatus for neurodegenerative diseases of the present invention.

[0024] Figure 5 This is a transcranial ultrasound image positioning diagram of a neurodegenerative disease ultrasound therapeutic device before the treatment of Parkinson's disease. (The left picture shows the midbrain of a Parkinson's disease patient (outlined by a white solid line) with significantly enhanced substantia nigra echoes (outlined by a white dotted line); the right picture shows the midbrain of a normal person.)

[0025] Figure 6 This is a near-infrared brain function signal monitoring diagram of a neurodegenerative disease ultrasonic therapeutic apparatus for treating an ALS patient of the present invention (left: normal person; right: ALS patient). DETAILED DESCRIPTION

[0026] The specific embodiments of the present invention are further described below. It should be noted that the description of these embodiments is used to help understand the present invention, but does not constitute a limitation of the present invention. In addition, the technical features involved in the embodiments described below can be combined with each other as long as they do not conflict with each other.

[0027] The experimental methods in the following examples are conventional methods unless otherwise specified, and the experimental materials used in the following examples are commercially available unless otherwise specified.

[0028] Example 1 Ultrasonic therapeutic apparatus for neurodegenerative diseases

[0029] An ultrasonic therapeutic device for neurodegenerative diseases, comprising: a host and a helmet assembly;

[0030] The host is provided with a power supply module, a touch screen, an ultrasonic host, a main control module, a near-infrared light transmitting module, and a near-infrared light receiving module; the touch screen, the ultrasonic host, the near-infrared light transmitting module, and the near-infrared light receiving module are electrically connected to the main control module respectively; the power supply module is electrically connected to the touch screen, the ultrasonic host, the near-infrared light transmitting module, the near-infrared light receiving module, and the main control module; there are multiple near-infrared light source probes, which are electrically connected to the near-infrared light transmitting module respectively; there are multiple near-infrared light receiving probes, which are electrically connected to the near-infrared light receiving module respectively; the ultrasonic transmitting probe and the ultrasonic receiving probe are electrically connected to the ultrasonic host;

[0031] The helmet assembly is provided with a probe fixing assembly 20, which includes an annular rod 201, a connecting portion 202, an adjusting buckle 1 203, an adjusting buckle 204, a hemispherical frame 205, a connecting piece 206, and a movable adjusting assembly 207; the hemispherical frame 205 is composed of a plurality of mutually connected slide rails and vertical rods, the bottom of the vertical rod is connected to the annular rod 201, the adjusting buckle 204 is arranged on the annular rod 201, connecting pieces 206 are arranged on both sides of the annular rod 201, the connecting piece 206 is connected with the connecting portion 202, the adjusting buckle 1 203 is arranged on the connecting portion 202, the near-infrared light source probe 9 and the near-infrared light receiving probe 11 are arranged on the hemispherical frame 205, the movable adjusting assembly 207 includes a slide rail 1 208, a slide rail 209, a guide sleeve 1 2071, a connecting rod 2072, and a guide sleeve 2073, and the movable adjusting assembly 207 is moved by the guide sleeve 1 2071 It is arranged between the upper and lower adjacent slide rails, and the two guide sleeves 2071 are connected by a connecting rod 2072. The guide sleeve 2073 is arranged on the connecting rod 2072. The ultrasonic transmitting probe 7 and the ultrasonic receiving probe 8 are respectively arranged on both sides of the guide sleeve 2073; the movable adjustment component 207 has two groups, which are respectively arranged on both sides of the rear part of the hemispherical frame 205 structure to perform ultrasonic treatment on both sides of the back of the brain; an ultrasonic transducer is also arranged on the probe fixing component, and the host is electrically connected to the ultrasonic transducer. The ultrasonic stimulation position is determined by intracranial ultrasonic imaging of the ultrasonic transmitting probe 7 and the ultrasonic receiving probe 8. The ultrasonic stimulation position is the clearest position of intracranial ultrasonic imaging. The ultrasonic treatment intensity is adjusted in real time by the host according to the condition of the disease and the ultrasonic stimulation position, and the treatment position is adjusted in real time by the movable adjustment component 207. The near-infrared light source probe 9 and the near-infrared light receiving probe 11 realize near-infrared brain function imaging monitoring, and the treatment effect can be monitored in real time.

[0032] Specifically, ultrasonic coupling stickers are provided on the ultrasonic transmitting probe 7 and the ultrasonic receiving probe 8 .

[0033] Example 2 Method of using an ultrasonic therapeutic device for treating neurodegenerative diseases

[0034] A method for using an ultrasonic therapeutic apparatus for neurodegenerative diseases, characterized in that it comprises the following steps:

[0035] S1: Put the probe fixing assembly 20 on the patient's head, start the near-infrared light transmitting module 5 and the near-infrared light receiving module 6 to perform near-infrared brain function imaging monitoring on the patient through the near-infrared light source probe 9 and the near-infrared light receiving probe 11, start the ultrasound host 3, and perform intracranial ultrasound imaging through the ultrasound transmitting probe 7 and the ultrasound receiving probe 8 to determine the ultrasound stimulation position;

[0036] S2: Adjust the movable adjustment component 207 so that the ultrasonic transmitting probe 7 and the ultrasonic receiving probe 8 are aligned with the ultrasonic stimulation position in S1. For Parkinson's disease, the functional nucleus located is the substantia nigra and striatum area; for ALS, the functional nucleus area located is the motor cortex area; for Alzheimer's disease, the area of ​​insufficient cerebral microblood flow shown by near-infrared brain functional imaging is widely irradiated.

[0037] S3: The ultrasonic transmitting probe 7 generates ultrasonic waves toward the ultrasonic stimulation position, and the ultrasonic receiving probe 8 receives the feedback sound wave intensity to monitor the treatment intensity in real time; the near-infrared light receiving probe 11 monitors the near-infrared cerebral blood flow signal in real time to grasp the real-time treatment effect;

[0038] Specifically, the ultrasound stimulation position is the area of ​​insufficient cerebral microblood flow shown by near-infrared brain functional imaging; the changes in the content of oxygenated hemoglobin and deoxygenated hemoglobin in the microcirculation of the intracranial cerebral cortex are mainly monitored;

[0039] Specifically, the ultrasound stimulation position is the position where the intracranial ultrasound imaging is clearest.

[0040] Specifically, the ultrasound focus diameter range of the ultrasound emitted in step S3 is 1 mm to 20 mm, and the ultrasound intensity is 0.5 w / cm 2 ~3w / cm 2 .

[0041] Specifically, the number of ultrasound transmitting probes varies according to different diseases. For ALS, the anterior gyrus of the brain needs to be irradiated, which is a large area, so multiple probes, such as 4, can be used; for Parkinson's disease, only 2 probes are needed through bilateral temporal windows.

[0042] Furthermore, the device provided by the present invention can be used to treat a variety of diseases, which will be described in detail below with reference to specific cases.

[0043] Example 3 Treatment of Parkinson's disease

[0044] Taking Parkinson's transcranial ultrasound stimulation treatment as an example, the steps are as follows:

[0045] Bring an ultrasound therapy device, perform ultrasound testing, find the position and plane where the substantia nigra and striatum are most clearly displayed, measure the proximal and distal depths of the substantia nigra and striatum from the probe, and mark them. Use an ultrasound probe that matches the focal length and focus range with the depth of the substantia nigra, turn on ultrasound irradiation at the marked point three times a day for 30 minutes each time, or follow the doctor's advice. The feedback signal of cerebral blood flow received by infrared signals and the ratio of oxygenated hemoglobin concentration to deoxygenated hemoglobin concentration are used to evaluate the immediate effect of irradiation. If the oxygenated hemoglobin concentration does not reach the calibration value, the irradiation time can be extended. Its beneficial effects are: by increasing the microblood flow in the lesion site of the brain and the "massage" effect (referred to as: cell massage) produced by the mechanical action of ultrasound on brain cells, the self-repair ability of nerve cells in the lesion site is enhanced, and harmful substances in the site are removed. Use ultrasound imaging to locate the lesion site of the patient.

[0046] Example 4 Treatment of Alzheimer's disease

[0047] Taking transcranial ultrasound stimulation treatment for Alzheimer's disease as an example, the steps are as follows:

[0048] Bring the ultrasound therapy device, perform ultrasound testing, find the area where the cerebral cortex shows the clearest image, measure the depth and front-to-back distance of the cerebral cortex from the ultrasound probe, and mark it. Use a weakly focused ultrasound probe to adjust the ultrasound power in different areas of the brain. For areas with clear ultrasound imaging, the power range is 0.5 to 1w / cm 2 For areas of the brain that are not clearly visible on ultrasound imaging, increase the ultrasound irradiation power to 0.6-2w / cm 2 Irradiation. Turn on ultrasound for whole brain irradiation three times a day, 30 minutes each time, or as directed by a doctor. The feedback signal of cerebral blood flow received by infrared signals and the ratio of oxygenated hemoglobin concentration to deoxygenated hemoglobin concentration are used to evaluate the immediate effect of irradiation. If the oxygenated hemoglobin concentration does not reach the calibration value, the irradiation time can be extended. Its beneficial effects are: by increasing the microblood flow in the lesion area of ​​the brain and the "massage" effect of the mechanical action of ultrasound on brain cells (referred to as: cell massage), the self-repair ability of nerve cells in the lesion area is enhanced, and harmful substances in the area are removed.

[0049] Example 5 Improvement and treatment of insomnia

[0050] Taking the improvement and treatment of insomnia as an example, the steps are as follows:

[0051] Bring an ultrasound therapy device, perform ultrasound testing, find the position and plane where the pineal gland is most clearly displayed, measure the proximal and distal depths of the pineal gland from the probe, and the front-to-back distance, and make a mark. Use an ultrasound probe that matches the focal length and focus range with the depth of the pineal gland, and turn on ultrasound irradiation at the marked point three times a day for 30 minutes each time, or follow the doctor's advice. The feedback signal of cerebral blood flow received by infrared signals and the ratio of oxygenated hemoglobin concentration to deoxygenated hemoglobin concentration are used to evaluate the immediate effect of irradiation. If the oxygenated hemoglobin concentration does not reach the calibration value, the irradiation time can be extended. By increasing the microblood flow of the pineal gland and the "massage" effect of the mechanical action of ultrasound on brain cells, the self-repair ability of nerve cells in the lesion area is enhanced, and harmful substances in the area are removed to promote the production of melatonin to enhance sleep quality.

[0052] Example 6 Treatment of Wilson's disease

[0053] Taking the treatment of Wilson's disease as an example, the steps are as follows:

[0054] Bring an ultrasound therapy device, perform ultrasound imaging, find the position and plane where the lenticular nucleus in the brain is most clearly displayed, measure the proximal and distal depths of the lenticular nucleus from the probe, and the front-to-back distance, and make a mark. Individually customize an ultrasound probe with a focal length and focusing range that matches the depth of the lenticular nucleus, and turn on ultrasound irradiation at the marked point three times a day for 30 minutes each time, or as directed by a doctor. The feedback signal of cerebral blood flow received by infrared signals and the ratio of oxygenated hemoglobin concentration to deoxygenated hemoglobin concentration are used to evaluate the immediate effect of irradiation. If the oxygenated hemoglobin concentration does not reach the calibration value, the irradiation time can be extended. Its beneficial effects are: by increasing the microblood flow in the lenticular nucleus and the "massage" effect of the mechanical action of ultrasound on brain cells, the self-repair ability of nerve cells in the lesion site is enhanced, harmful substances in the site are removed, and the deposition of copper ions in the lenticular nucleus is reduced.

[0055] Example 7 Treatment of drug, tobacco and alcohol addiction

[0056] Taking the treatment of drug, tobacco and alcohol addiction as an example, the steps are as follows:

[0057] Bring an ultrasound therapy device, perform ultrasound testing, find the position and plane where the nucleus accumbens in the brain is most clearly displayed, measure the proximal and distal depths of the nucleus accumbens from the probe, and the front-to-back distance, and make a mark. Select an ultrasound probe with a focal length and focusing range that matches the depth of the nucleus accumbens, and turn on ultrasound irradiation at the marked point three times a day for 30 minutes each time, or follow the doctor's advice. The feedback signal of cerebral blood flow received by infrared signals and the ratio of oxygenated hemoglobin concentration to deoxygenated hemoglobin concentration are used to evaluate the immediate effect of irradiation. If the oxygenated hemoglobin concentration does not reach the calibration value, the irradiation time can be extended. Its beneficial effects are: by increasing the microblood flow in the nucleus accumbens and the "massage" effect of the mechanical action of ultrasound on brain cells, the self-repair ability of nerve cells in the lesion area is enhanced, and the proportion of related receptors on nerve cells is promoted to return to normal.

[0058] Example 8 Treatment of Amnesia

[0059] Taking the treatment of amnesia as an example, the steps are as follows:

[0060] Bring an ultrasound therapy device and use ultrasound detection to find the position and plane where the hippocampus in the brain is most clearly displayed. Measure the proximal and distal depths of the hippocampus from the probe, as well as the front-to-back distance, and make a mark. Adjust the position of the ultrasound probe so that its focal length and focus range match the depth of the hippocampus. Turn on the ultrasound irradiation at the marked point three times a day for 30 minutes each time, or as directed by a doctor. The feedback signal of cerebral blood flow received by infrared signals and the ratio of oxygenated hemoglobin concentration to deoxygenated hemoglobin concentration are used to evaluate the immediate effect of irradiation. If the oxygenated hemoglobin concentration does not reach the calibration value, the irradiation time can be extended. By increasing the microblood flow in the hippocampus and the "massage" effect of the mechanical action of ultrasound on brain cells, the self-repair ability of nerve cells in the lesion area is enhanced, and the connection between neurons is promoted.

[0061] Compared with the prior art, the technical solution proposed by the present invention achieves the therapeutic effect by increasing microcirculation through continuous stimulation with low-intensity weakly focused ultrasound without damaging the functional nuclei. The device has good portability, high integration, small size, low cost, and can meet the requirements for home use; the patient only needs to wear the helmet assembly on the head and control the host to complete the treatment, which is convenient to use.

Claims

1. An ultrasonic therapeutic apparatus for treating neurodegenerative diseases, comprising: Host (10) and helmet assembly; The helmet assembly is provided with a probe fixing assembly (20), which comprises an annular rod (201), a connecting portion (202), an adjustment buckle 1 (203), an adjustment buckle 2 (204), a hemispherical frame (205), a connecting piece (206), and a movable adjustment assembly (207); the hemispherical frame (205) is composed of a plurality of mutually connected slide rails and vertical rods, the bottom of the vertical rod is connected to the annular rod (201), the adjustment buckle 2 (204) is arranged on the annular rod (201), and the annular Connecting pieces (206) are arranged on both sides of the rod (201), the connecting piece (206) is connected to a connecting portion (202), the adjusting buckle (203) is arranged on the connecting portion (202), the near-infrared light source probe (9) and the near-infrared light receiving probe (11) are arranged on the hemispherical frame (205), the movable adjusting component (207) comprises a slide rail (208), a slide rail (209), a guide sleeve (2071), a connecting rod (2072), a guide sleeve (2073), and the movable adjusting component ( The guide sleeve 207 is arranged between the upper and lower adjacent slide rails through the guide sleeve 1 (2071), the two guide sleeves 1 (2071) are connected by a connecting rod (2072), the guide sleeve 2 (2073) is arranged on the connecting rod (2072), and the ultrasonic transmitting probe (7) and the ultrasonic receiving probe (8) are respectively arranged on both sides of the guide sleeve 2 (2073); the movable adjustment component (207) has two groups, which are respectively arranged on both sides of the rear part of the hemispherical frame (205) structure to perform ultrasonic treatment on both sides of the back of the head; the probe fixing component is also provided An ultrasonic transducer is arranged, and the host is electrically connected to the ultrasonic transducer. The ultrasonic stimulation position is determined by intracranial ultrasonic imaging of an ultrasonic transmitting probe (7) and an ultrasonic receiving probe (8). The ultrasonic stimulation position is the clearest position of intracranial ultrasonic imaging. The ultrasonic treatment intensity is adjusted in real time by the host according to the condition of the disease and the ultrasonic stimulation position. The treatment position is adjusted in real time by moving the adjustment component (207). The near-infrared light source probe (9) and the near-infrared light receiving probe (11) realize near-infrared brain function imaging monitoring, and the treatment effect can be monitored in real time.

2. The ultrasonic therapeutic apparatus for treating neurodegenerative diseases according to claim 1, characterized in that: The host (10) is provided with a power supply module, a touch screen, an ultrasonic host, a main control module, a near-infrared light transmitting module, and a near-infrared light receiving module; the touch screen, the ultrasonic host, the near-infrared light transmitting module, and the near-infrared light receiving module are electrically connected to the main control module respectively; the power supply module is electrically connected to the touch screen, the ultrasonic host, the near-infrared light transmitting module, the near-infrared light receiving module, and the main control module; there are a plurality of near-infrared light source probes, which are electrically connected to the near-infrared light transmitting modules respectively; there are a plurality of near-infrared light receiving probes, which are electrically connected to the near-infrared light receiving modules respectively; the ultrasonic transmitting probe and the ultrasonic receiving probe are electrically connected to the ultrasonic host.

3. An ultrasonic therapeutic apparatus for treating neurodegenerative diseases as claimed in claim 1, wherein the application scope of the ultrasonic therapeutic apparatus for treating neurodegenerative diseases includes the treatment and improvement of Parkinson's disease, amyotrophic lateral sclerosis, hepatolenticular degeneration, Alzheimer's disease, insomnia, drug, tobacco and alcohol addiction and / or amnesia.

Images